Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Core Insights - Dyadic Applied BioSolutions and Inzymes ApS are set to commercialize recombinant non-animal bovine chymosin in 2026, a significant enzyme for cheese production, following successful development activities [1][2] Company Overview - Dyadic Applied BioSolutions is a global biotechnology company focused on producing precision-engineered, animal-free proteins and enzymes for various applications, including life sciences and food [1][5] - Inzymes ApS specializes in the development and commercialization of high-performance enzymes for sustainable food and beverage applications [1][6] Market Context - The global market for dairy processing enzymes is estimated to be between $1.5 billion and $2.0 billion annually, driven by increasing cheese consumption and demand for sustainable alternatives to traditional animal-sourced enzymes [3] Partnership and Development - The completion of development activities under the collaboration agreement between Dyadic and Inzymes marks a contractual milestone, resulting in a $200,000 milestone payment to Dyadic and eligibility for future royalties [2][4] - The partnership aims to leverage Dyadic's microbial expression platforms and Inzymes' commercialization expertise to meet evolving customer demands for enzyme performance and reliability [4] Future Prospects - Additional non-animal dairy enzyme candidates are progressing under the collaboration, indicating potential expansion in the market for fermentation-derived food enzymes [4]